Novel Association of KLRC4-KLRK1 Gene Polymorphisms with Susceptibility and Progression of Antithyroid Drug-Induced Agranulocytosis

 

 Buy Article Permissions and Reprints

Abstract

Objective Antithyroid drug (ATD)-induced agranulocytosis (TIA) is the most serious adverse effect during ATD treatment of Graves’ disease (GD). Previously, the MICA gene was reported to be associated with TIA. MICA protein is an important ligand for the NKG2D protein, which is encoded by the KLRK1 gene and KLRC4-KLRK1 read-through transcription. This study further investigated the association between KLRC4-KLRK1 gene polymorphisms and susceptibility to TIA.

Methods Twenty-eight candidate single nucleotide polymorphisms (SNPs) on KLRC4-KLRK1 read-through transcription were evaluated by the iPLEX MassARRAY system in 209 GD control patients and 38 TIA cases.

Results A significant association of rs2734565 polymorphism with TIA was found (p=0.02, OR=1.80, 95% CI=1.09–2.96). The haplotype C-A-A-C-G, including rs2734565-C, was associated with a significantly higher risk of TIA (p=4.79E-09, OR=8.361, 95% CI=3.737–18.707). In addition, the interval time from hyperthyroidism to agranulocytosis onset was shorter in patients carrying the rs2734565-C allele than in non-carrying groups (45.00 (14.00–6570.00) d vs. 1080.00 (30.00–3600.00) d, p=0.046), and the interval from ATD treatment to agranulocytosis onset was also shorter in patients carrying rs2734565-C allele (29.00 (13.00–75.00) d vs. 57.50 (21.00–240.00) d, p=0.023).

Conclusions The findings suggest that the KLRC4-KLRK1 gene polymorphism is associated with susceptibility and progression of ATD-induced agranulocytosis. Patients carrying the rs2734565-C allele had a higher susceptibility and faster onset time of TIA.

Publication History

Received: 19 June 2023
Received: 04 October 2023

Accepted: 30 October 2023

Article published online:
18 January 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352: 905-917 DOI: 10.1056/NEJMra042972.
  CrossrefPubMedGoogle Scholar
• 2 Watanabe N, Narimatsu H, Noh JY. et al. Antithyroid drug-induced hematopoietic damage: A retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease. J Clin Endocrinol Metab 2012; 97: E49-E53 DOI: 10.1210/jc.2011-2221.
  CrossrefPubMedGoogle Scholar
• 3 He Y, Li J, Zheng J. et al. Emphasis on the early diagnosis of antithyroid drug-induced agranulocytosis: Retrospective analysis over 16 years at one Chinese center. J Endocrinol Invest 2017; 40: 733-740 DOI: 10.1007/s40618-017-0626-x.
  CrossrefPubMedGoogle Scholar
• 4 Kim HK, Yoon JH, Jeon MJ. et al. Characteristics of Korean patients with antithyroid drug-induced agranulocytosis: A multicenter study in Korea. Endocrinol Metab (Seoul) 2015; 30: 475-480 DOI: 10.3803/EnM.2015.30.4.475.
  CrossrefPubMedGoogle Scholar
• 5 Nakamura H, Miyauchi A, Miyawaki N. et al. Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 2013; 98: 4776-4783 DOI: 10.1210/jc.2013-2569.
  CrossrefPubMedGoogle Scholar
• 6 Tomkins M, Tudor RM, Smith D. et al. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis and agranulocytosis in a patient with Graves’ disease. Endocrinol Diabetes Metab Case Rep 2020; 2020: 19-0135 DOI: 10.1530/EDM-19-0135.
  CrossrefPubMedGoogle Scholar
• 7 Thao MP, Tuan PVA, Linh LGH. et al. Association of HLA-B*38:02 with antithyroid drug-induced agranulocytosis in Kinh Vietnamese patients. Int J Endocrinol 2018; 2018: 7965346 DOI: 10.1155/2018/7965346.
  CrossrefPubMedGoogle Scholar
• 8 He Y, Zheng J, Zhang Q. et al. Association of HLA-B and HLA-DRB1 polymorphisms with antithyroid drug-induced agranulocytosis in a Han population from northern China. Sci Rep 2017; 7: 11950 DOI: 10.1038/s41598-017-12350-2.
  CrossrefPubMedGoogle Scholar
• 9 Hallberg P, Eriksson N, Ibanez L. et al. Genetic variants associated with antithyroid drug-induced agranulocytosis: A genome-wide association study in a European population. Lancet Diabetes Endocrinol 2016; 4: 507-516 DOI: 10.1016/S2213-8587(16)00113-3.
  CrossrefPubMedGoogle Scholar
• 10 Cheung CL, Sing CW, Tang CS. et al. HLA-B*38:02:01 predicts carbimazole/methimazole-induced agranulocytosis. Clin Pharmacol Ther 2016; 99: 555-561 DOI: 10.1002/cpt.309.
  CrossrefPubMedGoogle Scholar
• 11 Chen PL, Shih SR, Wang PW. et al. Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study. Nat Commun 2015; 6: 7633 DOI: 10.1038/ncomms8633.
  CrossrefPubMedGoogle Scholar
• 12 Ma P, Chen P, Gao J. et al. Association of MICA gene polymorphisms with thionamide-induced agranulocytosis. J Endocrinol Invest 2021; 44: 363-369 DOI: 10.1007/s40618-020-01319-0.
  CrossrefPubMedGoogle Scholar
• 13 Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res 2015; 3: 575-582 DOI: 10.1158/2326-6066.CIR-15-0098.
  CrossrefPubMedGoogle Scholar
• 14 Wensveen FM, Jelencic V, Polic B. NKG2D: A master regulator of immune cell responsiveness. Front Immunol 2018; 9: 441 DOI: 10.3389/fimmu.2018.00441.
  CrossrefPubMedGoogle Scholar
• 15 Gimeno L, Martinez-Banaclocha H, Bernardo MV. et al. NKG2D polymorphism in melanoma patients from southeastern Spain. Cancers (Basel) 2019; 11: 438 DOI: 10.3390/cancers11040438.
  CrossrefPubMedGoogle Scholar
• 16 Mariaselvam CM, Tamouza R, Krishnamoorthy R. et al. Association of NKG2D gene variants with susceptibility and severity of rheumatoid arthritis. Clin Exp Immunol 2017; 187: 369-375 DOI: 10.1111/cei.12891.
  CrossrefPubMedGoogle Scholar
• 17 Ma J, Guo X, Wu X. et al. Association of NKG2D genetic polymorphism with susceptibility to chronic hepatitis B in a Han Chinese population. J Med Virol 2010; 82: 1501-1507 DOI: 10.1002/jmv.21855.
  CrossrefPubMedGoogle Scholar
• 18 Melum E, Buch S, Schafmayer C. et al. Investigation of cholangiocarcinoma associated NKG2D polymorphisms in colorectal carcinoma. Int J Cancer 2008; 123: 241-242 DOI: 10.1002/ijc.23517.
  CrossrefPubMedGoogle Scholar
• 19 Vazquez-Gonzalez WG, Martinez-Alvarez JC, Arrazola-Garcia A. et al. Haplotype block 1 variant (HB-1v) of the NKG2 family of receptors. Human Immunology 2019; 80: 842-847 DOI: 10.1016/j.humimm.2019.07.276.
  CrossrefPubMedGoogle Scholar
• 20 Wadsworth CA, Dixon PH, Taylor-Robinson S. et al. Polymorphisms in natural killer cell receptor protein 2D (NKG2D) as a risk factor for cholangiocarcinoma. J Clin Exp Hepatol 2019; 9: 171-175 DOI: 10.1016/j.jceh.2018.06.521.
  CrossrefPubMedGoogle Scholar
• 21 Salmaninejad A, Zamani MR, Shabgah AG. et al. Behçet’s disease: An immunogenetic perspective. J Cell Physiol 2019; 234: 8055-8074 DOI: 10.1002/jcp.27576.
  CrossrefPubMedGoogle Scholar
• 22 Tan W, Liu M, Wang L. et al. Novel immune-related genes in the tumor microenvironment with prognostic value in breast cancer. BMC Cancer 2021; 21: 126 DOI: 10.1186/s12885-021-07837-1.
  CrossrefPubMedGoogle Scholar
• 23 Li P, Lu M, Shi J. et al. Dual roles of neutrophils in metastatic colonization are governed by the host NK cell status. Nat Commun 2020; 11: 4387 DOI: 10.1038/s41467-020-18125-0.
  CrossrefPubMedGoogle Scholar
• 24 Jiangtao C, Yingzhen K, Qian W. et al. MapGene2Chrom, a tool to draw gene physical map based on Perl and SVG languages. Yi Chuan 2015; 37: 91-97 DOI: 10.16288/j.yczz.2015.01.013.
  CrossrefPubMedGoogle Scholar
• 25 World Health Organization (WHO)–Uppsala Monitoring Centre: Uppsala S. The use of the WHO-UMC system for standardised case causality assessment. [EB/OL]. 2013 Available at http://who-umc.org/Graphics/24734.pdf
  PubMedGoogle Scholar
• 26 Naranjo CA, Busto U, Sellers EM. et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245 DOI: 10.1038/clpt.1981.154.
  CrossrefPubMedGoogle Scholar
• 27 Andres E, Lorenzo Villalba N, Mourot-Cottet R. et al. Severe neutropenia and agranulocytosis related to antithyroid drugs: A study of 30 cases managed in a single reference center. Medicines (Basel) 2020; 7: 15 DOI: 10.3390/medicines7030015.
  CrossrefPubMedGoogle Scholar
• 28 Yang J, Zhong J, Zhou LZ. et al. Sudden onset agranulocytosis and hepatotoxicity after taking methimazole. Intern Med 2012; 51: 2189-2192 DOI: 10.2169/internalmedicine.51.7845.
  CrossrefPubMedGoogle Scholar
• 29 Small KS, Hedman AK, Grundberg E. et al. Identification of an imprinted master trans regulator at the KLF14 locus related to multiple metabolic phenotypes. Nat Genet 2011; 43: 561-564 DOI: 10.1038/ng.833.
  CrossrefPubMedGoogle Scholar
• 30 Douer D, Eisenstein Z. Methimazole-induced agranulocytosis: Growth inhibition of myeloid progenitor cells by the patient’s serum. Eur J Haematol 1988; 40: 91-94 DOI: 10.1111/j.1600-0609.1988.tb00803.x.
  CrossrefPubMedGoogle Scholar
• 31 Thoren FB, Riise RE, Ousback J. et al. Human NK Cells induce neutrophil apoptosis via an NKp46- and Fas-dependent mechanism. J Immunol 2012; 188: 1668-1674 DOI: 10.4049/jimmunol.1102002.
  CrossrefPubMedGoogle Scholar
• 32 Robinet P, Baychelier F, Fontaine T. et al. A polysaccharide virulence factor of a human fungal pathogen induces neutrophil apoptosis via NK cells. J Immunol 2014; 192: 5332-5342 DOI: 10.4049/jimmunol.1303180.
  CrossrefPubMedGoogle Scholar
• 33 Gong X, Chen P, Ma P. et al. MICA polymorphisms associated with antithyroid drug-induced agranulocytosis in the Chinese Han population. Immun Inflamm Dis 2020; 8: 695-703 DOI: 10.1002/iid3.359.
  CrossrefPubMedGoogle Scholar

• Supplementary Material